SeekingAlpha · Aug 7, 2026
Apyx Medical Corporation (APYX) Q2 2026 Earnings Call Transcript
Apyx Medical Corporation (APYX) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsCharles Goodwin - President, CEO & DirectorMatthew...
AP
NASDAQ · APYX
Apyx Medical Corporation
Healthcare · Medical - Devices
$2.90
Up+$0.01 (+0.35%)
Updated Sep 12, 2026, 1:17 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 134.17M
- P/E ratio
- -9.16
- Dividend yield
- 0.00%
- 52-week range
- $2.76 – $5.08
- Volume
- 161.33K
- Avg. volume
- 107.62K
Price performance
APYX price history
1M range · 0 trading sessions · Daily adjusted prices
APYX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest APYX news
The latest Smart Investors Daily articles mentioning APYX.
Stock researchCompany · Overview
APYX research
Overview
Company profile and research snapshot.
Company profile
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $8.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 11, 2026 | Craig-Hallum | Buy | — |
| Mar 11, 2026 | BTIG | Buy | — |
| Dec 16, 2025 | Roth Capital | Buy | — |
| Nov 12, 2025 | Citizens | Market Outperform | — |
News briefing
No generated briefing is available yet.
ChartMill · Aug 6, 2026
Apyx Medical (NASDAQ:APYX) Shares Dip Despite Q2 Earnings Beat
APYX Medical beats Q2 estimates with 22% revenue growth to $13.88M, but stock dips 6.5% after recent rally. Growth driven by AYON adoption.
Benzinga · Aug 6, 2026
Apyx Medical Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $13.884M Beat $13.175M Estimate
Apyx Medical (NASDAQ:APYX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 22.22 percent increase over losses of $(0.09) per share from the
Benzinga · Aug 6, 2026
Apyx Medical Affirms FY2026 Sales Guidance of $59.000M-$60.000M vs $59.554M Est
Apyx Medical (NASDAQ:APYX) affirms FY2026 sales outlook from $59.000 million-$60.000 million to $59.000 million-$60.000 million vs $59.554 million estimate.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
